Roohi Ismail-Khan - Moffitt Cancer Center

基本信息

Career Trajectory

Bio

My current research interests are in cardio-oncology and women's cancers. My overall goal of clinical research is to minimize long term toxicity in patients who undergo chemotherapy and targeted therapy.

Research Interests

Papers共 89 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), As Monotherapy and in Combination with Abemaciclib, in Endometrioid Endometrial Cancer (EEC): Results from the EMBER Phase 1a/1b Study

Kan Yonemori,Kalyan Banda,Valentina Boni,Joohyuk Sohn,Tarek Meniawy,Janine Margaret Lombard,Peter A. Kaufman, Debra L. Richardson, Laura Bender Somme,Koji Matsumoto,Karthik Giridhar,Jose Angel Garcia Saenz,Hans Prenen,Bernard Doger de Speville Uribe,Don S. Dizon,Javier Garcia-Corbacho, Yujia Li,Bastien Nguyen,Roohi Ismail-Khan,Patrick Neven

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

Abstract 6427: Phase II Study of Trametinib Alone and in Combination with Uprosertib in Patients with Metastatic Triple Negative Breast Cancer Previously Treated with Chemotherapy: OSU 13317

Vishnu Prasath,Hinda Boutrid,Ewa Mrozek,Maryam Lustberg, Robert Weslowski,Rachel Layman,Mahmoud Abdel-Rasoul,Cynthia Timmers,Erin MacRae,G. Thomas Budd,Lyndsay Harris,Claudine Isaacs,Roohi Ismail-Khan,Elizabeth Claire Dees,Andrew S. Poklepovic, Helen X. Chen,Miguel Villalona-Calero,William Carson, Gary L. Johnson,Daniel G. Stover,Bhuvaneswari Ramaswamy

Cancer Researchno. 6_Supplement (2024): 6427-6427

Cited0Views0Bibtex

Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination with Human Epidermal Growth Factor Receptor 2 (HER2) Directed Therapy, with or Without Abemaciclib, in Estrogen Receptor (ER) Positive, HER2 Positive Advanced Breast Cancer (abc): EMBER Phase 1a/1b Study

Manali A. Bhave,Komal L. Jhaveri,Peter A. Kaufman,Philippe Georges Aftimos,Janine Margaret Lombard,Kostandinos Sideras,Seock-Ah Im,Cynthia X. Ma,Kuo-Ting Lee,Sung-Bae Kim, Yujia Li,Eunice Yuen,Shawn T. Estrem,Bastien Nguyen, Francesca Bacchion,Roohi Ismail-Khan,Muralidhar Beeram,Joohyuk Sohn

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, As Monotherapy and in Combination with Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Journal of clinical oncology official journal of the American Society of Clinical Oncologypp.JCO2302733-JCO2302733, (2024)

Cited0Views0WOSBibtex

Abstract OT1-01-02: EMBER-4: A Phase 3 Adjuvant Trial of Imlunestrant Vs Standard Endocrine Therapy (ET) in Patients with ER+, HER2- Early Breast Cancer (EBC) with an Increased Risk of Recurrence Who Have Previously Received 2 to 5 Years of Adjuvant ET

Komal Jhaveri,Joyce O’Shaughnessy,Fabrice Andre,Matthew P. Goetz,Nadia Harbeck,Miguel Martín,Francois-Clement Bidard,Zachary M. Thomas,Suzanne Young,Roohi Ismail-Khan,Lillian M. Smyth,Michael Gnant

Cancer Researchno. 5_Supplement (2023): OT1-01

Cited0Views0Bibtex

EMBER-4: a Phase 3 Adjuvant Trial of Imlunestrant Vs Standard Endocrine Therapy in Patients with ER+, HER2− Early Breast Cancer with an Increased Risk of Recurrence Who Have Previously Received 2 to 5 Years of Adjuvant ET

Komal Jhaveri,Joyce O'Shaughnessy,Fabrice Andre,Matthew P. Goetz,Nadia Harbeck,Miguel Martin,Francois-Clement Bidard,Zachary M. Thomas,Suzanne Young,Roohi Ismail-Khan,Lillian M. Smyth,Michael Gnant

CANCER RESEARCHno. 5 (2023)

Cited0Views0Bibtex

COVID-19 Severity and Cardiovascular Outcomes in SARS-CoV-2-infected Patients with Cancer and Cardiovascular Disease

Melissa Y. Y. Moey,Cassandra Hennessy,Benjamin French,Jeremy L. Warner,Matthew D. Tucker,Daniel J. Hausrath,Dimpy P. Shah,Jeanne M. DeCara,Ziad Bakouny,Chris Labaki,Toni K. Choueiri,Susan Dent,Nausheen Akhter,Roohi Ismail-Khan,Lisa Tachiki,David Slosky,Tamar S. Polonsky,Joy A. Awosika, Audrey Crago,Trisha Wise-Draper,Nino Balanchivadze,Clara Hwang,Leslie A. Fecher,Cyndi Gonzalez Gomez,Brandon Hayes-Lattin,Michael J. Glover,Sumit A. Shah,Dharmesh Gopalakrishnan,Elizabeth A. Griffiths,Daniel H. Kwon,Vadim S. Koshkin,Sana Mahmood,Babar Bashir,Taylor Nonato,Pedram Razavi,Rana R. McKay,Gayathri Nagaraj, Eric Oligino,Matthew Puc, Polina Tregubenko,Elizabeth M. Wulff-Burchfield,Zhuoer Xie,Thorvardur R. Halfdanarson,Dimitrios Farmakiotis,Elizabeth J. Klein,Elizabeth V. Robilotti,Gregory J. Riely, Jean-Bernard Durand,Salim S. Hayek,Lavanya Kondapalli,Stephanie Berg,Timothy E. O'Connor,Mehmet A. Bilen,Cecilia Castellano,Melissa K. Accordino,Blau Sibel,Lisa B. Weissmann,Chinmay Jani,Daniel B. Flora,Lawrence Rudski,Miriam Santos Dutra,Bouganim Nathaniel,Erika Ruiz-Garcia,Diana Vilar-Compte,Shilpa Gupta,Alicia Morgans,Anju Nohria

Translational oncology (2023): 101709-101709

Cited1Views0WOSBibtex

Abstract P6-10-06: A Preoperative Window-of-opportunity Study of Imlunestrant in Estrogen Receptor-Positive, HER2-negative Early Breast Cancer: Results from the EMBER-2 Study

Patrick Neven, Nicole Stahl,Maria Vidal,Miguel Martín, Nadia Harbeck,Peter A. Kaufman,Francois-Clement Bidard, Peter A. Fasching,Philippe Aftimos,Erika Hamilton,Stacey Carter,Peter Schmid,Duncan Wheatley,Manali Bhave,Kelly K. Hunt,Swati A. Kulkarni,Roohi Ismail-Khan,Claudia Karacsonyi,Shawn T. Estrem,Umut Ozbek,Bastien Nguyen,Eva Ciruelos

Cancer researchno. 5_Supplement (2023): P6-06

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn